Cytosorbents Corporation’s CTSO share price has dipped by 5.17%, which has investors questioning if this is right time to buy ...

Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Ind ...

PRINCETON, N.J., April 4, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using ...

The initial term of the agreement is three years, and is subject to annual minimum guaranteed orders of CytoSorb® to maintain exclusivity. Mr. Stephen Bailey, Managing Director of L.IN.C., stated ...

The Series B Right Warrants are exercisable commencing on their date of issuance at an exercise price equal to 90% of the 5-day volume weighted average price of our common stock over the last 5 ...

PRINCETON, N.J., April 4, 2025 /PRNewswire/ -- CytoSorbents Corporation (CTSO) (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac ...

CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents’ flagship product, CytoSorb®, is approved in the European ...

CytoSorbents’ flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval ...